Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals.
-
Clinical Benefit
Substantial
The actual benefit of MIRCERA is substantial.
Clinical Added Value
no clinical added value
MIRCERA offers no improvement in actual benefit (level V) compared to the other erythropoiesis-stimulating agents that are indicated in the correction of anaemia associated with chronic kidney disease.
Listen
